Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (361-370 of 441) with videos related to

Pageof 45
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2020
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosisArmand Abergel, Tarik Asselah, Arianne Mallat, et al.
Digestive Diseases and Sciences|April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in FranceDenis Ouzan, Dominique Larrey, Dominique Guyader, et al.
Hepatology (Baltimore, Md.)|June 25, 2016
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patientsDamien Ulveling, Sigrid Le Clerc, Aurélie Cobat, et al.
Annals of Internal Medicine|September 24, 2019
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice GuidelineCraig E Gordon, Marina C Berenguer, Wahid Doss, et al.
Health Science Reports|April 3, 2019
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)Tarik Asselah, Negar Niki Alami, Christophe Moreno, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.
JHEP Reports : Innovation in Hepatology|January 1, 2025
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 studyJean-Charles Nault, Nanthara Sritharan, Gontran Verset, et al.
Cell Reports|June 29, 2022
Early IFNβ secretion determines variable downstream IL-12p70 responses upon TLR4 activationCeline Posseme, Alba Llibre, Bruno Charbit, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Pageof 45

Showing results (361-370 of 441) with videos related to

Sort By:
Pageof 45
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2020
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosisArmand Abergel, Tarik Asselah, Arianne Mallat, et al.
Digestive Diseases and Sciences|April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in FranceDenis Ouzan, Dominique Larrey, Dominique Guyader, et al.
Hepatology (Baltimore, Md.)|June 25, 2016
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patientsDamien Ulveling, Sigrid Le Clerc, Aurélie Cobat, et al.
Annals of Internal Medicine|September 24, 2019
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice GuidelineCraig E Gordon, Marina C Berenguer, Wahid Doss, et al.
Health Science Reports|April 3, 2019
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)Tarik Asselah, Negar Niki Alami, Christophe Moreno, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.
JHEP Reports : Innovation in Hepatology|January 1, 2025
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 studyJean-Charles Nault, Nanthara Sritharan, Gontran Verset, et al.
Cell Reports|June 29, 2022
Early IFNβ secretion determines variable downstream IL-12p70 responses upon TLR4 activationCeline Posseme, Alba Llibre, Bruno Charbit, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Pageof 45